The French biotech company ScreenCell is developing an innovative blood filtration technology designed to improve the monitoring of solid tumors. At the heart of its approach are circulating tumor cells (CTCs), which are considered key markers of metastatic progression.
“These cells are released by the primary tumor and circulate in the blood before colonizing other organs,” explains Cécile Autant, the company’s head of quality and regulatory affairs. Detecting them is a major challenge for better understanding how cancers progress and tailoring treatments.
Toward non-invasive monitoring of solid tumors
The innovation developed by ScreenCell is based on a physical characteristic of CTCs: they are larger than conventional blood cells. Using a patented filtration system, the company is able to isolate these cells directly from a blood sample. Two devices have been designed: one for cytological analysis, the other for molecular biology applications to characterize the isolated cells.
This “liquid biopsy” technology could offer a less invasive alternative to traditional biopsies, while enabling more regular monitoring of patients.
French technology for the detection of metastases
To validate the clinical potential of its solution, ScreenCell is currently conducting several clinical trials. In partnership with Gustave Roussy, one study focuses on metastatic melanoma. A second, conducted with Clinique Hartmann, targets breast cancer. A new project is also set to begin shortly with McGill University, focusing on colorectal cancer.
Historically based in Paris, the company recently decided to expand part of its operations to Besançon to be closer to its industrial subcontractor. This move could also help attract talent from schools in the Franche-Comté region.